Levi & Korsinsky is investigating the Board of Directors of Chelsea Therapeutics International, Ltd. (“Chelsea Therapeutics” or “the Company”) (NasdaqCM:CHTP) for possible breaches of fiduciary duty and other violations of state law in connection with the sale of the Company to H. Lundbeck A/S.

Click here to learn more about the investigation: http://zlk.9nl.com/chelsea-therapeutics-chtp, or call: 877-363-5972. There is no cost or obligation to you.

Under the terms of the transaction, Chelsea Therapeutics shareholders will receive $6.44 and contingent value rights that may pay up to $1.50 for each share of Chelsea Therapeutics stock they own. The investigation concerns whether the Chelsea Therapeutics Board of Directors breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether H. Lundbeck A/S is underpaying for Chelsea Therapeutics shares.

If you own Chelsea Therapeutics common stock and wish to obtain additional information, please contact Joseph E. Levi, Esq. either via email at jlevi@zlk.com or by telephone at (212) 363-7500, toll-free: (877) 363-5972, or visit http://zlk.9nl.com/chelsea-therapeutics-chtp.

Levi & Korsinsky is a national firm with offices in New York, New Jersey, Connecticut, and Washington D.C. The firm's 26 attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. The attorneys at Levi & Korsinsky have been appointed by numerous courts throughout the country to serve as lead counsel on behalf of shareholders in major securities lawsuits and have successfully recovered multimillion-dollar damages awards on behalf of investors. Attorney advertising. Prior results do not guarantee similar outcomes.

Copyright Business Wire 2010